Weinstock A, et al. - In this prospective study of children with Lennox-Gastaut syndrome, researchers tested the efficacy of clobazam as adjunctive therapy for seizure reduction as well as improvement in behavior and quality of life (QOL) as reported by parents. In this 6-week, 4 phase study, they included 10 patients with Lennox-Gastaut syndrome (aged 3-11 years). Patients had improved indices of QOL, including physical activities, well-being, cognition, social activities, behavior, general health, and overall QOL. The Quality of Life in Childhood Epilepsy (QOLCE) questionnaire showed significant improvement in cognition, social activities, behavior, and overall QOL. In all patients with documented baseline seizures (8/10), some level of improvement was seen, with 5 showing significant improvement (95%-100% reduction) and 3 showing minor improvement (7%-23% reduction). In patients taking clobazam, an overall trend towards positive well-being was seen with this adjunct therapy in children with Lennox-Gastaut syndrome.